

H1 2016



Key Metrics for Technology and Life Sciences Initial Public Offerings

H1 2016

Fenwick
FENWICK & WEST LLP

Key Metrics for Technology and Life Sciences Initial Public Offerings

H1 2016

Survey Introduction and Background

This report has been developed as a resource for our clients and friends interested in understanding recent IPO activity of technology and life sciences companies. This information comprises a number of graphs and charts reflecting selected statistics that we believe provide useful information about activity in these markets. This is followed by the listing of technology and life sciences IPOs priced in the first half of 2016 and second half 2015. We hope that you find this useful. Please contact Daniel J. Winnike at dwinnike@fenwick.com or Jeffrey R. Vetter at jvetter@fenwick.com if you care to discuss this information or, as always, contact members of your client service team for more information.

Survey Contents

Survey Results	2
Offerings Completed.....	3
Size of Offerings, Red Herring Midpoint.....	4
Size of Offerings, Final IPO Price.....	5
Aggregate Amount Raised, Red Herring Midpoint	6
Aggregate Amount Raised, Final IPO Price.....	7
Price Changes Between the Red Herring and Initial Offering Price	8
Confidential Submissions	14
Price Changes Around the Expiration of the Lock-Up.....	15
Insider Participation	16
List of Technology Offerings	17
List of Life Sciences Offerings	19
Methodology.....	22

Survey Results

Signs of life in the second quarter, though IPO pipeline remains modest

The sharp decline in U.S. equity markets at the beginning of 2016 ushered in the slowest yearly start for technology and life sciences IPOs since the collapse of the markets in 2008-2009. The market's subsequent rebound did little to accelerate the pace, although the four technology IPOs in the first half all priced in the second quarter. While life sciences IPOs fell to their lowest half-year rate since 2011, their totals far outpaced technology IPOs. Life sciences companies completed 16 deals in the first half of 2016 compared to four completed by technology companies in the same period. These numbers show a further decline from the second half of 2015, where there were 26 life sciences and 13 technology IPOs completed. There were no blockbuster large deals completed in the first half of the year, with the largest transaction, a life sciences deal, raising approximately \$240 million. Otherwise deal sizes ranged from \$35 to \$160 million with over 50% of life sciences IPOs in the range of \$50-75 million.

Perhaps not surprisingly, pricing was a challenge for life sciences IPOs in the first half. Nine of the 16 deals priced below the red herring range and none above. Of the limited set of four technology transactions, one priced above and one priced below the range. After-market performance was more positive, with half of the life sciences deals trading up in the first day of trading, compared to seven trading down, and three of the technology deals trading up. The balance of the deals closed their first day of trading at the IPO price.


Insider participation continued to be a prominent feature of life sciences IPOs. Insiders purchased shares in 12 of the 16 completed deals. The level of insider participation was high in these deals, with the smallest percentage subscribed to by insiders being just over 20% of the offering proceeds and on average approximately 50% insider participation for deals with that feature. In six of these transactions, insiders subscribed for over 50% of the deal and in two life sciences IPOs, insiders purchased more than 60% of the offerings.

With the impending election, it is unclear how the rest of 2016 will fare for high technology and life sciences companies seeking to go public. However, there are 20 and 34 registration statements for high technology and life sciences IPOs, respectively, currently on file publicly with the SEC. The rest of the year still looks very modest.

Offerings Completed

The graph below shows the number of technology and life sciences IPOs completed during each quarter of 2012, 2013, 2014, 2015 and H1 2016.

IPOs PER QUARTER 2012–H1 2016



Technology—U.S.

Technology—International


Life Sciences—U.S.

Life Sciences—International


Size of Offerings, Red Herring Midpoint

The following scatter graphs plot technology and life sciences IPOs completed during the first half of 2016 and second half of 2015 in terms of the initial offering price per share and number of shares offered based on the red herring stage of the offering. The second half 2015 graph excludes First Data Corporation with a deal size of \$3.0 billion as a significant outlier.

RED HERRING DEAL COMPARISON (MIDPOINT PRICE): 2016, FIRST HALF




RED HERRING DEAL COMPARISON (MIDPOINT PRICE): 2015, SECOND HALF




Size of Offerings, Final IPO Price

The following scatter graphs plot technology and life sciences IPOs completed during the first half of 2016 and second half of 2015 in terms of the initial offering price per share and number of shares offered based on actual pricing of the offering. The second half 2015 graph excludes First Data Corporation with a deal size of \$2.6 billion as a significant outlier.

IPO DEAL COMPARISON: 2016, FIRST HALF




IPO DEAL COMPARISON: 2015, SECOND HALF




Aggregate Amount Raised, Red Herring Midpoint

The following graphs provide information about aggregate deal size at the red herring stage in the first half of 2016 and second half of 2015.

DISTRIBUTION OF DEAL SIZE (RED HERRING MIDPOINT): 2016, FIRST HALF




Technology Deal Size Distribution




Life Sciences Deal Size Distribution

DISTRIBUTION OF DEAL SIZE (RED HERRING MIDPOINT): 2015, SECOND HALF



Technology Deal Size Distribution




Life Sciences Deal Size Distribution


Aggregate Amount Raised, Final IPO Price

The following graphs provide information about aggregate deal size based on the actual pricing of the offering in the first half of 2016 and second half of 2015.

DISTRIBUTION OF DEAL SIZE (FINAL IPO PRICE): 2016, FIRST HALF




Technology Deal Size Distribution




Life Sciences Deal Size Distribution

DISTRIBUTION OF DEAL SIZE (FINAL IPO PRICE): 2015, SECOND HALF



Technology Deal Size Distribution




Life Sciences Deal Size Distribution


Price Changes Between the Red Herring and Initial Offering Price

Estimating the offering price for the IPO in the red herring prospectus and pricing the IPO upon completion of marketing efforts are processes that are part science and art. The graphs below show the median and average prices for technology and life sciences IPOs from the red herring stage to the actual public offering price to the close price on the first day of trading, for the first half of 2016 and second half of 2015.

MEDIAN PRICES FOR TECHNOLOGY & LIFE SCIENCES IPO DEALS




AVERAGE PRICES FOR TECHNOLOGY & LIFE SCIENCES IPO DEALS




Price Changes (continued)

The first two graphs show the percentage of technology and life sciences IPOs with a final price that falls above, within and below the red herring range in the first half of 2016 compared with the second half of 2015. The lower graphs show the percentage of technology and life sciences deals that closed up, down or flat on their first day of trading in the second half of 2016 compared with the second half of 2015.


RELATION OF FINAL IPO PRICE TO ORIGINAL RED HERRING RANGE (% OF DEALS)
2016, FIRST HALF




RELATION OF FINAL IPO PRICE TO ORIGINAL RED HERRING RANGE (% OF DEALS)
2015, SECOND HALF



RELATION OF PRICE AT 1ST DAY CLOSE TO FINAL IPO PRICE (% OF DEALS)
2016, FIRST HALF




RELATION OF PRICE AT 1ST DAY CLOSE TO FINAL IPO PRICE (% OF DEALS)
2015, SECOND HALF




Price Changes *(continued)*

The graphs below show the five technology company IPOs with the largest percentage gain (four in 2016), and those with a loss, on the first day of trading for IPOs completed in the first half of 2016 and second half of 2015.

BIGGEST MOVERS – IPO PRICE TO PRICE AT 1ST DAY CLOSE 2016, FIRST HALF



BIGGEST MOVERS – IPO PRICE TO PRICE AT 1ST DAY CLOSE 2015, SECOND HALF



Price Changes (continued)

The graphs below show the five life sciences company IPOs with the largest percentage gain and loss on the first day of trading for IPOs completed in the first half of 2016 and second half of 2015.

BIGGEST MOVERS – IPO PRICE TO PRICE AT 1ST DAY CLOSE 2016, FIRST HALF


BIGGEST MOVERS – IPO PRICE TO PRICE AT 1ST DAY CLOSE 2015, SECOND HALF




Price Changes (continued)

The graphs below show the technology company IPOs with the largest percentage increase, and largest percentage decrease, from the red herring midpoint to the actual initial public offering price for IPOs completed in the first half of 2016 and second half of 2015.

BIGGEST MOVERS – RED HERRING PRICE TO FINAL IPO PRICE 2016, FIRST HALF




BIGGEST MOVERS – RED HERRING PRICE TO FINAL IPO PRICE 2015, SECOND HALF




Price Changes *(continued)*

The graphs below show the five life sciences company IPOs with the largest percentage increase, and largest percentage decrease, from the red herring midpoint to the actual initial public offering price for IPOs completed in the first half of 2016 (with only four pricing at or above the midpoint) and second half of 2015.

BIGGEST MOVERS – RED HERRING PRICE TO FINAL IPO PRICE 2016, FIRST HALF




BIGGEST MOVERS – RED HERRING PRICE TO FINAL IPO PRICE 2015, SECOND HALF




Confidential Submissions

For deals that began with a confidential filing, the graphs below show the number of days between the initial confidential submission and pricing. The graphs display the percentage of deals that priced within each 15-day period from the initial confidential submission date.

DISTRIBUTION OF DAYS BETWEEN INITIAL CONFIDENTIAL SUBMISSION AND FINAL PRICING
2016, FIRST HALF




DISTRIBUTION OF DAYS BETWEEN INITIAL CONFIDENTIAL SUBMISSION AND FINAL PRICING
2015, SECOND HALF




Price Changes Around the Expiration of the Lock-Up

In order to assist the development of an orderly market for the shares being offered, IPO underwriters require the stockholders of the offering company to agree not to sell shares of the company’s common stock for a specified period without the underwriters’ consent. Customarily, this period is 180 days and applies equally to all holders delivering the “lock-up” agreement, although in a few instances the lock-up may roll off in stages, and different holders may be subject to different restrictive periods. Upon expiration of the lock-up period, there generally is an influx of “supply,” as pre-IPO stockholders have their first ability to sell shares into the public market. The graphs below show the average and median changes in the closing trading price of the subject company shares for the period beginning two weeks prior, and ending two weeks following, the scheduled expiration of the lock-up period for lock-ups expiring in the first half and second half of 2015. Those companies completing IPOs in the second half of 2014 and a follow-on offering within 180 days are excluded from the first graph below. Those companies completing IPOs in the second half of 2016 and a follow-on offering within 180 days are excluded from the second graph below.

PERCENT CHANGE OF SHARE PRICES SURROUNDING END OF LOCK-UP PERIOD 2016, FIRST HALF




PERCENT CHANGE OF SHARE PRICES SURROUNDING END OF LOCK-UP PERIOD 2015, SECOND HALF




Insider Participation

The charts below show the percentage of life sciences and technology IPOs where the final prospectus indicated that specified “insiders” had expressed an interest in purchasing shares in the offering. Insiders are directors and officers of a company as well as existing stockholders. In this case, insiders are typically existing investors who buy additional shares in the IPO. Among life sciences IPOs with insider interest, the inset shows the breakdown of shares set aside for insiders.

PERCENTAGE OF DEALS WITH INSIDER PARTICIPATION AND PERCENTAGE OF OFFERING MADE AVAILABLE TO INSIDERS 2016, FIRST HALF



PERCENTAGE OF DEALS WITH INSIDER PARTICIPATION AND PERCENTAGE OF OFFERING MADE AVAILABLE TO INSIDERS 2015, SECOND HALF



Technology Offerings: H1 2016^{1, 2}

COMPANY NAME / TICKER SYMBOL	RED HERRING MIDPOINT	PRICED	FINAL SHARES ³	FINAL PRICING	FINAL DEAL SIZE
SecureWorks Corp. NasdaqGS:SCWX	\$16.50	4/2016	8,000,000	\$14.00	\$112,000,000
Acacia Communications, Inc. NasdaqGS:ACIA	\$22.00	5/2016	4,500,000	\$23.00	\$103,500,000
Nant Health, LLC NasdaqGS:NH	\$14.00	6/2016	6,500,000	\$14.00	\$91,000,000
Twilio Inc. NYSE:TWLO	\$13.00	6/2016	10,000,000	\$15.00	\$150,000,000

¹The survey does not include offerings on the OTC Bulletin Board, Nasdaq Capital Market or those with proceeds of less than \$10 million.

²Rows shaded in orange represent International Technology IPOs.

³Final share numbers do not reflect any exercise of the over-allotment option.

Technology Offerings: H2 2015^{1, 2}

COMPANY NAME / TICKER SYMBOL	RED HERRING MIDPOINT	PRICED	FINAL SHARES ³	FINAL PRICING	FINAL DEAL SIZE
Ooma, Inc. NYSE: OOMA	\$17.00	7/2015	5,000,000	\$13.00	\$65,000,000
Rapid7, Inc. NasdaqGM: RPD	\$14.00	7/2015	6,450,000	\$16.00	\$103,200,000
Sunrun Inc. NasdaqGS: RUN	\$14.00	8/2015	17,900,000	\$14.00	\$250,600,000
Pure Storage, Inc. NYSE: PSTG	\$17.00	10/2015	25,000,000	\$17.00	\$425,000,000
CPI Card Group Inc. NasdaqGS: PMTS	\$17.00	10/2015	15,000,000	\$10.00	\$150,000,000
First Data Corporation NYSE: FDC	\$19.00	10/2015	160,000,000	\$16.00	\$2,560,000,000
Xtera Communications NasdaqGM: XCOM	\$10.00	11/2015	5,000,000	\$5.00	\$25,000,000
Instructure, Inc. NYSE: INST	\$17.00	11/2015	4,400,000	\$16.00	\$70,400,000
Match Group, Inc. NasdaqGS: MTCH	\$13.00	11/2015	33,333,333	\$12.00	\$399,999,996
Mimecast Limited NasdaqGS: MIME	\$11.00	11/2015	7,750,000	\$10.00	\$77,500,000
Square, Inc. NYSE: SQ	\$12.00	11/2015	27,000,000	\$9.00	\$243,000,000
Atlassian Corporation PLC NasdaqGS: TEAM	\$17.50	12/2015	22,000,000	\$21.00	\$462,000,000
Yirendai Ltd. NYSE: YRD	\$10.00	12/2015	7,500,000	\$10.00	\$75,000,000

¹The survey does not include offerings on the OTC Bulletin Board, Nasdaq Capital Market or those with proceeds of less than \$10 million.

²Rows shaded in orange represent International Technology IPOs.

³Final share numbers do not reflect any exercise of the over-allotment option.

Life Sciences Offerings: H1 2016^{1, 2}

COMPANY NAME / TICKER SYMBOL	RED HERRING MIDPOINT	PRICED	FINAL SHARES ³	FINAL PRICING	FINAL DEAL SIZE
Editas Medicine, Inc. NasdaqGS:EDIT	\$17.00	2/2016	5,900,000	\$16.00	\$94,400,000
BeiGene, Ltd. NasdaqGS:BGNE	\$23.00	2/2016	6,600,000	\$24.00	\$158,400,000
AveXis, Inc. NasdaqGS:AVXS	\$20.00	2/2016	4,750,000	\$20.00	\$95,000,000
Proteostasis Therapeutics, Inc. NasdaqGM:PTI	\$13.00	2/2016	6,250,000	\$8.00	\$50,000,000
Syndax Pharmaceuticals, Inc. NasdaqGS:SNDX	\$14.00	3/2016	4,400,000	\$12.00	\$52,800,000
Hutchison China MediTech Limited NasdaqGS:HCM	\$16.33	3/2016	7,500,000	\$13.50	\$101,250,000
Corvus Pharmaceuticals, Inc. NasdaqGM:CRVS	\$16.00	3/2016	4,700,000	\$15.00	\$70,500,000
Aeglea BioTherapeutics, Inc. NasdaqGM:AGLE	\$17.00	4/2016	5,000,000	\$10.00	\$50,000,000
Intellia Therapeutics, Inc. NasdaqGM:NTLA	\$17.00	5/2016	6,000,000	\$18.00	\$108,000,000
Oncobiologics, Inc. NasdaqGM:ONS	\$12.00	5/2016	5,833,334	\$6.00	\$35,000,004
Merus B.V. NasdaqGM:MRUS	\$15.00	5/2016	5,500,000	\$10.00	\$55,000,000
Cotiviti Holdings, Inc. NYSE:COTV	\$18.00	5/2016	12,500,000	\$19.00	\$237,500,000
Reata Pharmaceuticals, Inc. NasdaqGM:RETA	\$15.00	5/2016	5,500,000	\$11.00	\$60,500,000
Clearside Biomedical, Inc. NasdaqGM:CLSD	\$15.00	6/2016	7,200,000	\$7.00	\$50,400,000
Selecta Biosciences, Inc. NasdaqGM:SELB	\$15.00	6/2016	5,000,000	\$14.00	\$70,000,000
Syros Pharmaceuticals, Inc. NasdaqGS:SYRS	\$15.00	6/2016	4,000,000	\$12.50	\$50,000,000

¹The survey does not include offerings on the OTC Bulletin Board, Nasdaq Capital Market or those with proceeds of less than \$10 million.

²Rows shaded in blue represent International Life Sciences IPOs.

³Final share numbers do not reflect any exercise of the over-allotment option.

Life Sciences Offerings: H2 2015^{1, 2}

COMPANY NAME / TICKER SYMBOL	RED HERRING MIDPOINT	PRICED	FINAL SHARES ³	FINAL PRICING	FINAL DEAL SIZE
ConforMIS, Inc. NasdaqGS: CFMS	\$15.00	7/2015	9,000,000	\$15.00	\$135,000,000
Teladoc, Inc. NYSE: TDOC	\$16.00	7/2015	8,250,000	\$19.00	\$156,750,000
Natera, Inc. NasdaqGS: NTRA	\$16.00	7/2015	10,000,000	\$18.00	\$180,000,000
Chiasma, Inc. NasdaqGS: CHMA	\$14.00	7/2015	6,365,000	\$16.00	\$101,840,000
ProNAi Therapeutics, Inc. NasdaqGM: DNAI	\$15.00	7/2015	8,100,000	\$17.00	\$137,700,000
Neos Therapeutics, Inc. NasdaqGM: NEOS	\$15.00	7/2015	4,800,000	\$15.00	\$72,000,000
NantKwest, Inc. NasdaqGS: NK	\$21.50	7/2015	8,288,000	\$25.00	\$207,200,000
vTv Therapeutics Inc. NasdaqGM: VTVT	\$16.00	7/2015	7,812,500	\$15.00	\$117,187,500
Zynerba Pharmaceuticals NasdaqGM: ZYNE	\$14.00	8/2015	3,000,000	\$14.00	\$42,000,000
Aimmune Therapeutics, Inc. NasdaqGS: AIMT	\$15.00	8/2015	10,000,000	\$16.00	\$160,000,000
Global Blood Therapeutics, Inc. NasdaqGS: GBT	\$17.00	8/2015	6,000,000	\$20.00	\$120,000,000
REGENXBIO Inc. NasdaqGS: RGNX	\$18.00	9/2015	6,300,000	\$22.00	\$138,600,000
Nabriva Therapeutics AG NasdaqGM: NBRV	\$16.00	9/2015	9,000,000	\$10.25	\$92,250,000
Penumbra Inc. NYSE: PEN	\$26.50	9/2015	4,000,000	\$30.00	\$120,000,000
Mirna Therapeutics Inc. NasdaqGM: MIRN	\$14.00	10/2015	6,250,000	\$7.00	\$43,750,000
Edge Therapeutics Inc. NasdaqGS: EDGE	\$15.00	10/2015	7,315,151	\$11.00	\$80,466,661
NovoCure Limited NasdaqGS: NVCR	\$27.50	10/2015	7,500,000	\$22.00	\$165,000,000
Aclaris Therapeutics, Inc. NasdaqGS: ACRS	\$15.00	10/2015	5,000,000	\$11.00	\$55,000,000
CytomX Therapeutics, Inc. NasdaqGS: CTMX	\$15.00	10/2015	6,666,667	\$12.00	\$80,000,004
Strongbridge Biopharma NasdaqGS: SBBP	\$17.93	10/2015	2,500,000	\$10.00	\$25,000,000
Dimension Therapeutics, Inc. NasdaqGS: DMTX	\$15.00	10/2015	5,500,000	\$13.00	\$71,500,000
Myokardia NasdaqGS: MYOK	\$16.00	10/2015	5,437,500	\$10.00	\$54,375,000

¹The survey does not include offerings on the OTC Bulletin Board, Nasdaq Capital Market or those with proceeds of less than \$10 million.

²Rows shaded in blue represent International Life Sciences IPOs.

³Final share numbers do not reflect any exercise of the over-allotment option.

Life Sciences Offerings: H2 2015^{1,2} (continued)

COMPANY NAME / TICKER SYMBOL	RED HERRING MIDPOINT	PRICED	FINAL SHARES ³	FINAL PRICING	FINAL DEAL SIZE
Advanced Accelerator Applications SA NasdaqGS: AAAP	\$16.00	11/2015	4,688,000	\$16.00	\$75,008,000
Voyager Therapeutics, Inc. NasdaqGS: VYGR	\$16.00	11/2015	5,000,000	\$14.00	\$70,000,000
WAVE Life Sciences Pte. Ltd. NasdaqGM: WVE	\$16.00	11/2015	6,375,000	\$16.00	\$102,000,000
Mesoblast Limited NasdaqGS: MESO	\$12.10	11/2015	7,479,617	\$8.00	\$59,836,936

¹The survey does not include offerings on the OTC Bulletin Board, Nasdaq Capital Market or those with proceeds of less than \$10 million.

²Rows shaded in blue represent International Life Sciences IPOs.

³Final share numbers do not reflect any exercise of the over-allotment option.

Methodology

Data points used in the compilation and analysis of this information were gathered using a variety of resources, including, but not limited to, filings made with the U.S. Securities and Exchange Commission, lock-up expiration dates from EDGAR Online IPO Deal Data and daily stock-trading price data. The exact dates upon which lock-ups expired were estimated based on disclosure in the prospectuses and may further be approximate in the case of dates falling on holidays or weekends. Companies were assigned to the Technology and Life Sciences sectors based on SIC codes and other company descriptors.

The information in the graphs and tables regarding offering size does not reflect any exercise of the underwriters' over-allotment, or green shoe, option. Information at the red herring stage is based on the midpoint of the range and on the number of shares offered, as reflected on the cover page of the first preliminary, or red herring, prospectus. The information regarding the actual offering size is based on the price to the public and the aggregate number of shares offered, as reflected on the cover page of the final prospectus. The closing price on the first day of trading is the closing price on the company's primary exchange on the first day of public trading of the shares following the pricing of the offering.

Disclaimer

The preparation of the information contained herein involves assumptions, compilations and analysis, and there can be no assurance that the information provided herein is error-free. Neither Fenwick & West LLP nor any of its partners, associates, staff or agents shall have any liability for any information contained herein, including any errors or incompleteness. The contents of this report are not intended, and should not be considered, as legal advice or opinion.

Sign-Up Information

To be placed on an email list for future editions of this survey, please visit fenwick.com/iposurvey and go to the sign-up link at the bottom of the page.

© 2016 Fenwick & West LLP

¹The survey does not include offerings on the OTC Bulletin Board, Nasdaq Capital Market, or those with proceeds of less than \$10 million.

²Final share numbers do not reflect any exercise of the over-allotment option.



+15.18%

+9.12%

+4.34%